MCID: ANS025
MIFTS: 28

Anus Benign Neoplasm

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Anus Benign Neoplasm

MalaCards integrated aliases for Anus Benign Neoplasm:

Name: Anus Benign Neoplasm 12 15
Anal Neoplasm 12 17
Neoplasm of Anus 12
Anus Neoplasms 44
Anal Tumors 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4551
MeSH 44 D001005
NCIt 50 C2877
SNOMED-CT 67 126849006
UMLS 70 C0003463

Summaries for Anus Benign Neoplasm

MalaCards based summary : Anus Benign Neoplasm, also known as anal neoplasm, is related to anus sarcoma and anus cancer. An important gene associated with Anus Benign Neoplasm is MACROH2A2 (MacroH2A.2 Histone), and among its related pathways/superpathways is Necroptosis. The drugs Octreotide and Atezolizumab have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and pancreas.

Related Diseases for Anus Benign Neoplasm

Diseases related to Anus Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 anus sarcoma 11.0
2 anus cancer 10.1
3 anal canal carcinoma 10.0
4 anal canal adenocarcinoma 10.0
5 anal canal squamous cell carcinoma 10.0
6 adenocarcinoma 9.9
7 squamous cell papilloma 9.8
8 papilloma 9.8
9 anal squamous cell carcinoma 9.8
10 ureteral benign neoplasm 9.6 SALL3 KRT7

Graphical network of the top 20 diseases related to Anus Benign Neoplasm:



Diseases related to Anus Benign Neoplasm

Symptoms & Phenotypes for Anus Benign Neoplasm

Drugs & Therapeutics for Anus Benign Neoplasm

Drugs for Anus Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
2
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
3
Ipilimumab Approved Phase 3 477202-00-9
4
nivolumab Approved Phase 3 946414-94-4
5
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
6
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
7
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
8 Gastrointestinal Agents Phase 3
9 Antineoplastic Agents, Hormonal Phase 3
10 Antineoplastic Agents, Immunological Phase 3
11 Adjuvants, Immunologic Phase 3
12 Anesthetics Phase 3
13 Antibiotics, Antitubercular Phase 2, Phase 3
14 Mitomycins Phase 2, Phase 3
15 Anti-Bacterial Agents Phase 2, Phase 3
16 Antimetabolites Phase 2, Phase 3
17
Cidofovir Approved Phase 2 113852-37-2 60613
18
Formaldehyde Approved, Vet_approved Phase 2 50-00-0 712
19
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
20
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
21
Durvalumab Approved, Investigational Phase 2 1428935-60-7
22
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
23
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
24
Levoleucovorin Approved, Investigational Phase 1, Phase 2 68538-85-2 149436
25
leucovorin Approved Phase 1, Phase 2 58-05-9 6006
26
Niraparib Approved, Investigational Phase 1, Phase 2 1038915-60-4 24958200
27
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
28
Panitumumab Approved, Investigational Phase 1, Phase 2 339177-26-3 50070211
29
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
30
Pomalidomide Approved Phase 2 19171-19-8
31
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
32
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
33
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
34
Edetic Acid Approved, Vet_approved Phase 2 60-00-4, 62-33-9 6049
35
Pentetic acid Approved Phase 2 67-43-6
36
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
37
Palonosetron Approved, Investigational Phase 2 135729-56-5, 119904-90-4 148211
38
Manganese Approved, Nutraceutical Phase 1, Phase 2 7439-96-5 27854
39
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
40 Interleukin-12 Phase 1, Phase 2
41 Psychotropic Drugs Phase 2
42 Anticonvulsants Phase 2
43 Immunoglobulin G Phase 2
44 Immunoglobulins, Intravenous Phase 2
45 Antibodies, Monoclonal Phase 2
46 Histone Deacetylase Inhibitors Phase 2
47 Pharmaceutical Solutions Phase 1, Phase 2
48 Trace Elements Phase 1, Phase 2
49 Nutrients Phase 1, Phase 2
50 Micronutrients Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 168)
# Name Status NCT ID Phase Drugs
1 Randomized Trial to Evaluate Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy Unknown status NCT02369939 Phase 3 Mitomycin C;5-Fluorouracil
2 A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of 9vHPV (V503), a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women Completed NCT01651949 Phase 3
3 A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults Completed NCT01164722 Phase 3
4 A Randomized, Double Blind, Placebo-Controlled Phase III Study To Determine The Efficacy Of Sandostatin LAR® Depot (Octreotide Acetate) In Preventing Or Reducing The Severity Of Chemoradiation-Induced Diarrhea In Patients With Anal Or Rectal Cancer Completed NCT00075868 Phase 3 octreotide acetate
5 Second UK Phase III Anal Cancer Trial: A Trial of Chemoradiation and Maintenance Therapy for Patients With Anal Cancer Completed NCT00025090 Phase 3 cisplatin;fluorouracil;mitomycin C
6 A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal Completed NCT00003596 Phase 3 cisplatin;fluorouracil;mitomycin C
7 Intensification Therapy for Locally Advanced Epidermoid Cancer of the Anal Canal - Phase III Intergroup Study Completed NCT00003652 Phase 3 cisplatin;fluorouracil
8 A Randomized Non-inferiority Trial Evaluating the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors Recruiting NCT04157985 Phase 3 Continue PD-1/PD-L1 Inhibitors treatment
9 A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients Recruiting NCT04444921 Phase 3 Carboplatin;Paclitaxel
10 A Phase 3, Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9vHPV Vaccine in Japanese Males, 16 to 26 Years of Age. Recruiting NCT04635423 Phase 3
11 ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study Recruiting NCT02135419 Phase 3 imiquimod;fluorouracil
12 A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer Recruiting NCT03233711 Phase 3
13 Randomised Phase III Trial of Chemoradiotherapy With or Without Paclitaxel in Patients With Squamous-cell Anal Cancer Enrolling by invitation NCT02526953 Phase 3 Paclitaxel;Capecitabine;Capecitabine;Mitomycins;Mitomycins
14 Continuous Fluorouracil Plus Mitomycin C Versus Mitomycin C Plus Cisplatin As Chemotherapy Combination In Combined Radiochemotherapy For Locally Advanced Anal Cancer. A Phase II-III Study Terminated NCT00068744 Phase 2, Phase 3 cisplatin;fluorouracil;mitomycin C
15 Phase II Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer Unknown status NCT03381352 Phase 2 Capecitabine;Mitomycin C
16 A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand Unknown status NCT03302858 Phase 2
17 An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease Unknown status NCT02051868 Phase 2 Cisplatin;5-Fluorouracil (5-FU);Carboplatin;Paclitaxel
18 Phase II Study for Treatment of Anal HSIL Through Use of a Chinese Herbal Topical Cream Completed NCT00622440 Phase 2 AIJP (Arnebia Indigo Jade Pearl);Placebo
19 A Phase II, Prospective, Open-label, Pilot Study of the Tolerability, Safety, and Efficacy of Argon Plasma Coagulation for the Treatment of Anal Intraepithelial Neoplasia Grade 2 or 3 in HIV-positive Men Having Sex With Men Completed NCT00428285 Phase 2
20 Improving Pelvic Cancer Patient Chemoradiotherapy Outcomes With FLT PET Imaging Completed NCT01717391 Phase 2 fluorothymidine F 18
21 A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
22 Phase 2 Trial to Assess the Efficacy and Safety of Chemoradiation With 5-fluorouracil, Mytomicin C and Panitumumab as a Treatment for Anal Squamous Cell Carcinoma Completed NCT01285778 Phase 2 panitumumab, mytomicin C, 5-FU, radiation
23 Phase IIA Trial of 1% Topical Cidofovir for Treatment of High-Grade Perianal Squamous Intraepithelial Lesions in HIV-Infected Men and Women Completed NCT00550589 Phase 2 cidofovir
24 AMC-072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex With Males Completed NCT01209325 Phase 2
25 A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
26 A Phase II Evaluation of Dose-Painted Intensity-Modulated Radiation Therapy (IMRT) in Combination With 5-Fluorouracil (5-FU) and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal Completed NCT00423293 Phase 2 fluorouracil;mitomycin C
27 A Phase I/II Trial of SGN-00101 in the Treatment of High-Grade Anal Intraepithelial Neoplasia (AIN) in HIV-Positive Individuals Completed NCT00052897 Phase 1, Phase 2
28 A Phase II Study of Capecitabine (Xeloda)/Oxaliplatin (Eloxatin) With Concomitant Radiotherapy (XRT), XELOX/RT in Squamous Cell Carcinoma of the Anal Canal Completed NCT00093379 Phase 2 Capecitabine;Oxaliplatin
29 Phase II Trial of Combined Modality Therapy Plus Cetuximab in HIV-Associated Anal Carcinoma Completed NCT00324415 Phase 2 cisplatin;fluorouracil
30 Phase 2 Study of ADXS11-001 in Subjects With Persistent/Recurrent, Loco-Regional or Metastatic Squamous Cell Carcinoma of the Anorectal Canal Completed NCT02399813 Phase 2 ADXS11-001
31 A Prospective Pilot Study to Evaluate the Feasibility of Intensity Modulated Proton Therapy in Reducing Toxicity in Anal Cancer Recruiting NCT03018418 Phase 2 Chemotherapy
32 Phase I/II Trial of Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies Recruiting NCT04287868 Phase 1, Phase 2
33 A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) Recruiting NCT04166318 Phase 2 Capecitabine;Fluorouracil;Mitomycin
34 Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PD-L1/TGF-Beta Trap (M7824) in Subjects With HPV Positive Cancers Recruiting NCT04432597 Phase 1, Phase 2
35 The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab With Valproic Acid for the Treatment of Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
36 A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers Recruiting NCT03439085 Phase 2
37 Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: A Feasibility Trial Recruiting NCT03690921 Phase 2 Cisplatin;Fluorouracil
38 Phase II Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life Recruiting NCT02701088 Phase 2 5Fluorouracile and Mitomycin-C
39 A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) Recruiting NCT02628067 Phase 2
40 A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons Recruiting NCT02437851 Phase 2
41 Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. Recruiting NCT04230759 Phase 2 Chemotherapy;Durvalumab
42 A Phase 1 Trial for Patients With Newly Diagnosed Anal Cancer Treated With Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001 Recruiting NCT03386500 Phase 1, Phase 2 BMX-001
43 A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma Recruiting NCT03519295 Phase 2 MPDL3280A;mDCF
44 A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal (BISQUIT) Recruiting NCT03870607 Phase 2
45 Phase II Basket Trial Evaluating the Efficacy of a Combination of Pembrolizumab and Vorinostat in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma Recruiting NCT04357873 Phase 2 pembrolizumab; vorinostat
46 A Multicenter Phase 2 Clinical Trial of Pembrolizumab in Metastatic Anal Cancer Recruiting NCT02919969 Phase 2 Pembrolizumab
47 A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies Recruiting NCT03221400 Phase 1, Phase 2 PEN-866 Sodium;fluorouracil;Folinic acid;Niraparib
48 A Phase 2, Open Label, Study of VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL), (AIN2, AIN3, PAIN2, PAIN3) in Individuals That Are Seronegative for Human Immunodeficiency Virus (HIV)-1/2 Active, not recruiting NCT03499795 Phase 2
49 Phase I-II on Radiochemotherapy Combined With Panitumumab in the Treatment of Localised Epidermoid Carcinoma of the Anus Active, not recruiting NCT01581840 Phase 1, Phase 2 radiochemotherapy;Panitumumab
50 Phase II Trial of M7824 in Subjects With HPV Associated Malignancies Active, not recruiting NCT03427411 Phase 2 M7824

Search NIH Clinical Center for Anus Benign Neoplasm

Cochrane evidence based reviews: anus neoplasms

Genetic Tests for Anus Benign Neoplasm

Anatomical Context for Anus Benign Neoplasm

MalaCards organs/tissues related to Anus Benign Neoplasm:

40
Cervix, Lymph Node, Pancreas, T Cells, Liver

Publications for Anus Benign Neoplasm

Articles related to Anus Benign Neoplasm:

# Title Authors PMID Year
1
Rare case of granular cell tumor of perianal region: a case report and literature review. 61
33459105 2021
2
A rare case of perianal granular cell tumor: case report and literature review. 61
28603602 2017
3
Pathology of Anal Cancer. 61
27889037 2017
4
Loss of histone variant macroH2A2 expression associates with progression of anal neoplasm. 61
26658220 2016
5
[Screening of intraepithelial anal neoplasm]. 61
24210980 2014
6
[Anal endosonography in the diagnosis of anal neoplasm]. 61
12557448 2002
7
[Anal neoplasm. Considerations on 100 cases]. 61
5614746 1967

Variations for Anus Benign Neoplasm

Expression for Anus Benign Neoplasm

Search GEO for disease gene expression data for Anus Benign Neoplasm.

Pathways for Anus Benign Neoplasm

Pathways related to Anus Benign Neoplasm according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.03 MACROH2A2 H2AB2 H2AB1

GO Terms for Anus Benign Neoplasm

Cellular components related to Anus Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromosome GO:0005694 9.46 MACROH2A2 H2BW1 H2AB2 H2AB1
2 transcriptionally active chromatin GO:0035327 8.96 H2AB2 H2AB1
3 nucleosome GO:0000786 8.92 MACROH2A2 H2BW1 H2AB2 H2AB1

Biological processes related to Anus Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin silencing GO:0006342 9.13 MACROH2A2 H2AB2 H2AB1
2 nucleosome assembly GO:0006334 8.92 MACROH2A2 H2BW1 H2AB2 H2AB1

Molecular functions related to Anus Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.43 SALL3 MACROH2A2 H2BW1 H2AB2 H2AB1 EBF3
2 protein heterodimerization activity GO:0046982 8.92 MACROH2A2 H2BW1 H2AB2 H2AB1

Sources for Anus Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....